Free Trial
NYSEAMERICAN:NBY

NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis

NovaBay Pharmaceuticals logo
$0.73 +0.01 (+1.39%)
(As of 11/14/2024 ET)

About NovaBay Pharmaceuticals Stock (NYSEAMERICAN:NBY)

Key Stats

Today's Range
$0.70
$0.75
50-Day Range
N/A
52-Week Range
$0.36
$12.08
Volume
76,055 shs
Average Volume
994,079 shs
Market Capitalization
$3.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. It sells its products through the company's web stores, third-party online retailers and distribution partners. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

NovaBay Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
9th Percentile Overall Score

NBY MarketRank™: 

NovaBay Pharmaceuticals scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for NovaBay Pharmaceuticals.

  • Earnings Growth

    Earnings for NovaBay Pharmaceuticals are expected to grow in the coming year, from ($2.54) to ($0.55) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NovaBay Pharmaceuticals is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NovaBay Pharmaceuticals is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NovaBay Pharmaceuticals has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    18.15% of the outstanding shares of NovaBay Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    NovaBay Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NovaBay Pharmaceuticals has recently increased by 4,169.83%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    NovaBay Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    NovaBay Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    18.15% of the outstanding shares of NovaBay Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    NovaBay Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NovaBay Pharmaceuticals has recently increased by 4,169.83%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    NovaBay Pharmaceuticals has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for NovaBay Pharmaceuticals this week, compared to 0 articles on an average week.
  • Search Interest

    Only 2 people have searched for NBY on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NovaBay Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.30% of the stock of NovaBay Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 1.34% of the stock of NovaBay Pharmaceuticals is held by institutions.

  • Read more about NovaBay Pharmaceuticals' insider trading history.
Receive NBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NBY Stock News Headlines

Central Bank Abandons USD
Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold.
NovaBay Pharmaceuticals, Inc. (B9P0.F)
See More Headlines

NBY Stock Analysis - Frequently Asked Questions

NovaBay Pharmaceuticals' stock was trading at $0.1802 at the start of the year. Since then, NBY stock has increased by 294.1% and is now trading at $0.7101.
View the best growth stocks for 2024 here
.

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) posted its quarterly earnings results on Thursday, November, 11th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts' consensus estimates of ($1.40) by $0.35. The biopharmaceutical company had revenue of $1.84 million for the quarter. NovaBay Pharmaceuticals had a negative trailing twelve-month return on equity of 146.20% and a negative net margin of 79.70%.

NovaBay Pharmaceuticals shares reverse split on Wednesday, November 16th 2022. The 1-35 reverse split was announced on Wednesday, November 16th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that NovaBay Pharmaceuticals investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), Tesla (TSLA) and TherapeuticsMD (TXMD).

Company Calendar

Last Earnings
11/11/2021
Today
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:NBY
Employees
30
Year Founded
N/A

Profitability

Net Income
$-10,610,000.00
Pretax Margin
-79.70%

Debt

Sales & Book Value

Annual Sales
$14.40 million
Book Value
$1.53 per share

Miscellaneous

Free Float
4,160,000
Market Cap
$3.06 million
Optionable
Not Optionable
Beta
2.82
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NYSEAMERICAN:NBY) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners